|
Vaccine Comparison
SARS-CoV M protein DNA vaccine |
SARS-CoV N + SARS-CoV M DNA vaccine |
SARS-CoV N protein DNA vaccine |
Vaccine Information |
Vaccine Information |
Vaccine Information |
- Type: DNA vaccine
- Status: Research
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: mouse
- Antigen: membrane protein (M) (Shi et al., 2006)
- membrane protein (M) gene of SARS-CoV
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: DNA vaccine made from recombinant plasmid containing membrane protein (M) sequence constructed then expressed and purified from E. coli bacteria (Shi et al., 2006)
|
- Type: DNA vaccine
- Status: Research
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: mouse
- Antigen: N, membrane protein (M) (Shi et al., 2006)
- nucleocapsid protein (N) gene of SARS-CoV
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- membrane protein (M) gene of SARS-CoV
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: DNA vaccine made from recombinant plasmids containing membrane protein (M) and nucleocapsid protein (N) sequences constructed then expressed and purified from E. coli bacteria (Shi et al., 2006)
|
- Type: Subunit vaccine
- Status: Research
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: mouse
- Antigen: N (Shi et al., 2006)
- nucleocapsid protein (N) gene of SARS-CoV
gene engineering:
- Type: Recombinant protein preparation
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: DNA vaccine made from recombinant plasmid containing nucleocapsid protein (N) sequence constructed then expressed and purified from E. coli bacteria (Shi et al., 2006)
|
Host Response |
Host Response |
Host Response |
Mouse Response
|
Mouse Response
- Host Strain: Balb/c (Shi et al., 2006)
- Vaccination Protocol: 20 μg of intramuscular vaccine injection (Shi et al., 2006)
- Immune Response: Production of N-specific IgG antibodies (paricularly IgG2a), Lymphocyte proliferation, Production of IFN-γ, IL-2, IL-4, Increased CD4+ and CD8+ levels (Shi et al., 2006)
|
Mouse Response
- Vaccination Protocol: DNA-coated gold particles were prepared and delivered to the shaved abdominal regions of mice using a helium-driven gene gun (Bio-Rad) with a discharge pressure of 400 lb/in2. C57BL/6 mice were immunized with 2 μg of the plasmid encoding N protein. The mice received two boosters with the same dose at a 1-week interval. (Kim et al., 2004)
- Immune Response: Significantly increased neutralizing antibody titer to N protein DNA vaccine and significantl count of INF-gamma CD8_ lymphocytes within splenocytes (Kim et al., 2004)
- Challenge Protocol: Challenge Protocol: Vaccinated mice challenged with DNA encoding N and challenged these mice with Vac-N or Vac-WT (Recombinant vaccinnia virus expressing SARS N protein or wild-type vaccinia virus, respectively) intranasally or intravenously 1 week after the last vaccination (Kim et al., 2004)
- Efficacy: reduced viral titer load(Kim et al., 2004)
Mouse Response
- Host Strain: Balb/c (Shi et al., 2006)
- Vaccination Protocol: 20 μg of vaccine intramuscular injection (Shi et al., 2006)
- Immune Response: Production of N-specific IgG antibodies (paricularly IgG2a), Lymphocyte proliferation, Production of IFN-γ, IL-2, IL-4, Increased CD4+ and CD8+ levels
(Shi et al., 2006)
|
Vole Response
|
Vole Response
- Vaccination Protocol: 100 μg injected (Shi et al., 2006)
- Immune Response: increased N-specific antibodies compared to Vaccine 5732, increased lymphocyte proliferation specific to N antigen than Vaccine 5732 (Shi et al., 2006)
- Challenge Protocol: 100 μg injected (Shi et al., 2006)
- Efficacy: 6/7 voles protected (Shi et al., 2006)
|
Vole Response
- Host Strain: Microtus brandti raddes (Shi et al., 2006)
- Vaccination Protocol: 100 μg injected (Shi et al., 2006)
- Immune Response: increased N-specific antibodies, increased lymphocye proliferation specific to N antigen (Shi et al., 2006)
- Challenge Protocol: 100 μg injected three times at an interval of 7 days and then challenged with live SARS-CoV (PUMC01) (Shi et al., 2006)
|
References |
References |
References |
Shi et al., 2006: Shi SQ, Peng JP, Li YC, Qin C, Liang GD, Xu L, Yang Y, Wang JL, Sun QH. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Molecular immunology. 2006; 43(11); 1791-1798. [PubMed: 16423399].
|
Shi et al., 2006: Shi SQ, Peng JP, Li YC, Qin C, Liang GD, Xu L, Yang Y, Wang JL, Sun QH. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Molecular immunology. 2006; 43(11); 1791-1798. [PubMed: 16423399].
|
Shi et al., 2006: Shi SQ, Peng JP, Li YC, Qin C, Liang GD, Xu L, Yang Y, Wang JL, Sun QH. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Molecular immunology. 2006; 43(11); 1791-1798. [PubMed: 16423399].
|
|